Class Action Overview for Skye Bioscience, Inc.
On December 3, 2025, a significant notice was issued to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE) regarding a class action lawsuit. This action encourages all shareholders who purchased shares during the class period to interact with the Gross Law Firm to explore their legal options.
Important Registration Information
Shareholders who acquired shares of SKYE in the specified class period are strongly urged to reach out for possible inclusion as lead plaintiffs. Being appointed as a lead plaintiff is not necessary to be eligible for any potential recovery related to this class action.
Class Period and Deadline
CLASS PERIOD: The relevant time frame for this class action extends from November 4, 2024, to October 3, 2025. This means that anyone who bought shares of SKYE during this encounter potentially has a stake in the proceedings.
DEADLINE: It is crucial for shareholders to engage promptly, as the deadline to file for this class action is January 16, 2026. Time is of the essence for those looking to secure their claims in this case.
Allegations Against Skye Bioscience
This class action lawsuit raises serious allegations, claiming that during the class period, the defendants made materially false and misleading statements regarding the effectiveness and prospects of their primary product candidate, nimacimab. Investors were led to believe that the product's capabilities and potential were far less favorable than initially communicated, which constitutes a significant oversight by the company.
Next Steps for Concerned Shareholders
Once registered, shareholders will benefit from an advanced portfolio monitoring system that will keep them informed throughout the duration of the case. The role of a lead plaintiff, while important, is not required for participation. Every shareholder has the opportunity to play a role in seeking justice without any financial obligation.
Why Choose the Gross Law Firm?
The Gross Law Firm has established itself as a reputable entity dedicated to protecting investors' rights. Their mission is to stand against deceit and fraudulent practices while ensuring corporate accountability. Investors who have faced losses due to misleading actions from companies, including those like Skye Bioscience, Inc., can count on the firm for support in their recovery endeavors.
Contact Information
If you wish to get involved or need more information regarding this class action, please reach out to:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Frequently Asked Questions
What is the class period for the Skye Bioscience lawsuit?
The class period is from November 4, 2024, to October 3, 2025.
How can shareholders participate in the class action?
Shareholders can register with the Gross Law Firm to become involved in the proceedings.
What are the main allegations against Skye Bioscience?
The allegations include false and misleading statements regarding nimacimab’s effectiveness and commercial prospects.
Is there a deadline for registering in the class action?
Yes, shareholders must register by January 16, 2026.
What services does the Gross Law Firm provide to registered shareholders?
The firm offers portfolio monitoring services that provide updates throughout the case lifecycle.
